Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)
$2.7900
-0.2000 ( -7.31% ) 898.9K
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Market Data
Open
$2.7900
Previous close
$2.9900
Volume
898.9K
Market cap
$199.19M
Day range
$2.7550 - $3.0160
52 week range
$2.6600 - $18.0700
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 69 | Apr 09, 2024 |
8-k | 8K-related | 17 | Feb 27, 2024 |
10-k | Annual reports | 228 | Feb 27, 2024 |
8-k | 8K-related | 16 | Feb 15, 2024 |
4 | Insider transactions | 1 | Feb 12, 2024 |
4 | Insider transactions | 1 | Feb 12, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |